A transformative moment in the global fight against obesity has emerged with the announcement of positive topline results ...

Here are five oral obesity candidates that, according to Mizuho’s Graig Suvannavejh, could change the weight loss game.

Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 ATTAIN-1 trial, evaluating ...

Now, new clinical trial results suggest that an oral form of this medication may be coming soon—and the results so far are ...

The company said it planned to seek Food and Drug Administration approval for the drug, orforglipron, before the end of the ...

Orforglipron led to 11.5% placebo-adjusted weight loss at 72 weeks (among those who adhered to high-dose treatment) in Attain-1, versus 13.9% at 64 weeks in Oasis 4 for the 25-mg dose of oral ...

In the 72-week phase 3 ATTAIN-1 trial, the once-daily oral GLP-1 receptor agonist orforglipron led to substantial weight loss ...

Eli Lilly's orforglipron missed weight loss targets in a Phase 3 trial, but strong Q2 results and raised guidance highlight ...

Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight in a late-stage ...

Findings from key secondary endpoints showed 59.6% of patients taking orforglipron 36mg (highest dose) achieved a reduction in body weight of 10% or greater vs 8.6% of patients receiving placebo; ...

In an 18-month clinical trial of the experimental GLP-1 pill orforglipron, about 60 percent of people lost at least 10 ...